Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg e...

Descripción completa

Detalles Bibliográficos
Autores principales: van Oers, Marinus, Smolej, Lukas, Petrini, Mario, Offner, Fritz, Grosicki, Sebastian, Levin, Mark-David, Davis, Jaclyn, Banerjee, Hiya, Stefanelli, Tommaso, Hoever, Petra, Geisler, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893027/
https://www.ncbi.nlm.nih.gov/pubmed/31801940
http://dx.doi.org/10.1038/s41408-019-0260-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893027/
https://www.ncbi.nlm.nih.gov/pubmed/31801940
http://dx.doi.org/10.1038/s41408-019-0260-2

Ejemplares similares